Ellansé

Ellansé is a polycaprolactone (PCL) dermal implant made of PCL microspheres suspended in a CMC-containing carrier gel. The carrier contributes immediate structural correction, while the microspheres are discussed in relation to a later collagen response.

Ellansé is a particle-and-carrier product. It should not share assumed handling, placement, diffusion, or duration with Gouri simply because both are described as PCL injectables.

Quick reference

Field	Ellansé
Particulate component	PCL microspheres
Carrier	Gel containing phosphate-buffered saline, glycerin, and CMC
Broad composition	Commonly described as 30% PCL microspheres and 70% CMC-based carrier
Current SSCP variants	Ellansé-S and Ellansé-M
Presentation	Sterile, single-use, ready-to-use implant
Legal manufacturer	AQTIS Medical B.V.
Commercial company	Sinclair
Main comparison	Gouri’s manufacturer-described solubilized PCL system

Sinclair’s Summary of Safety and Clinical Performance (SSCP) identifies the components, S and M variants, legal manufacturer, classification, and supplied accessories (Sinclair SSCP 🔗).

Formulation and presentation

The SSCP describes Ellansé as a sterile, latex-free, non-pyrogenic, bioresorbable, non-permanent implant. Synthetic PCL microspheres are suspended in a carrier gel containing:

phosphate-buffered saline
glycerin
carboxymethylcellulose

Sinclair’s professional guide describes the product as approximately 30% PCL microspheres and 70% CMC gel carrier (Ellansé expert guide 🔗).

The SSCP states that the product is supplied with four 27G needles. That supplied accessory information does not establish that one needle or one technique is appropriate for every anatomy.

Immediate and delayed components

Component	Product-level interpretation
CMC-containing carrier gel	Provides immediate structural correction and distributes the implant
PCL microspheres	Remain as the particulate component associated with later tissue response

Sinclair describes visible improvement immediately after treatment followed by gradual collagen-related change (Sinclair Ellansé 🔗).

This sequence should not be converted into a claim that:

all immediate volume persists unchanged
all later volume is newly formed collagen
carrier resorption occurs on one exact timetable in every patient
the product is equivalent to an HA gel

Current and historical variants

The reviewed SSCP lists Ellansé-S and Ellansé-M. Older publications and regional materials may describe L or E variants and associate letters with nominal durations.

Injectable Index uses the current SSCP as the initial variant anchor. Historical or regional variants should be added only with:

exact market
current availability
current IFU
legal manufacturer
supported duration wording
date checked

Do not present an S/M letter, an older product name, or a polymer-degradation estimate as a guaranteed individual duration.

Intended use and regional scope

Sinclair’s current UK/EU-facing page states that Ellansé is indicated for subdermal implantation in the face for lasting correction of wrinkles and signs or conditions of facial aging.

This statement should not be rewritten as:

approval for every facial plane
approval for hands or body
universal availability
FDA approval
interchangeable use across all historical variants

Use the regulator or local IFU for the specific market.

Ellansé versus Gouri

Field	Ellansé	Gouri
PCL physical form	Microspheres	Manufacturer-described fully solubilized PCL
Carrier	CMC-containing gel	Product-specific solubilized-polymer system
Immediate structure	Carrier contributes immediate correction	Do not infer the same carrier behavior
Presentation	Ready-to-use implant	Product-specific presentation
Protocol transfer	Not supported	Not supported

The comparison is about physical product architecture. It is not evidence that either product is safer, distributes better, lasts longer, or is preferable for a particular anatomy.

Company and regulatory roles

Role	Supported relationship
Brand	Ellansé
Legal manufacturer in the reviewed SSCP	AQTIS Medical B.V., Utrecht, the Netherlands
Commercial portfolio	Sinclair
Swiss authorized representative in the reviewed SSCP	Sinclair Pharma GmbH branch context
Local approval holder or distributor	Market-specific

Sinclair’s current product page also identifies AQTIS Medical B.V. as manufacturer (Sinclair Ellansé 🔗).

The Sinclair company page keeps that manufacturing role separate from Sinclair’s portfolio and parent-company context.

Safety and limitations

Sinclair lists expected injection-related reactions and possible implant-related complications, including infection, lumps or nodules, inflammatory reactions, inadequate or excessive augmentation, and interference with circulation. Rare but serious events described for facial filler intravascular injection include visual impairment, blindness, ischemia, stroke, and tissue necrosis.

Product-specific safety interpretation should preserve:

variant
anatomy
plane and distribution
immediate versus delayed timing
inflammatory signs
vascular findings
previous implants and procedures

Ellansé is bioresorbable but does not have a simple product-wide enzymatic reversal pathway.

Nearby reference pages

Structural correction defines the immediate carrier role without converting it into a duration claim.
Immediate vs delayed effects separates carrier and PCL-related phases.
European Union regulation records the current EU intended-use and manufacturer evidence.
Clinical practice framework links product identity with longitudinal records and emergency readiness.
Vascular and visual emergencies keeps the non-HA product limitation explicit during handover.
Ellansé vs Gouri separates PCL microspheres from a manufacturer-described solubilized PCL system.
Ready-to-use vs reconstituted places the prefilled syringe in a handling comparison.
PCL explains why physical form is central to the category.
Radiesse provides another particle-and-CMC-carrier comparison with CaHA rather than PCL.
Juvelook uses a PDLLA + HA hybrid architecture.
Collagen Stimulators maps the wider product graph.